Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

According to a new major clinical trial known as the ESSENCE trial, semaglutide—better known as Ozempic when used for Type 2 diabetes, or Wegovy when prescribed for weight loss—may be doing more for ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening ...

A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.

More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.

Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

Two patients with MASH share their paths to diagnosis, including the challenges they faced and what it took to find answers.

All participants also received standard care for MASH. Participants got two liver biopsies to help evaluate the effects of semaglutide. About 56% of participants had type 2 diabetes, and about 73% ...